Pre-Conference Workshop Day
8:30 am Check in & Light Refreshments
Workshop A
9:30 am Tackling T-Cell Exhaustion Through Co-Stimulation to Improve Response Durability & Control Immune Activation
Synopsis
Join this workshop to unlock the full potential of T-cell engagers through costimulation. As we look to enhance T-cell activation beyond the traditional CD3 signal, incorporating co-stimulatory signals into the TCR cascade could be a game-changer for potency and specificity. Key insights from second-gen CAR-T therapies, where co-stimulation played a pivotal role in approvals, are shaping new trispecific engages that simultaneously target tumor cells and co-stimulate T-cells. In this session, we’ll dive into how this approach is boosting cytokine release and refining the balance
between efficacy and toxicity.
Discussion Points:
- Integrating co-stimulation into the TCR signaling cascade to enhance T-cell activation
- Exploring trispecific T-cell engagers to co-stimulate and target tumors simultaneously
- Balancing cytokine release and potency by optimizing co-stimulatory signals for controlled immune activation
- Limiting cytokine release to only within the tumor
12:30 pm Lunch Break & Networking
Workshop B
1:30 pm Powering Up: Next-Gen T-Cell Engager Combinations for Dual Sided Tumor Control
Synopsis
Join this workshop to explore cutting-edge combination strategies that aim to boost the efficacy and durability of TCEs in oncological indications. As we move beyond single-agent approaches, the focus is on combining TCEs with other modalities, including ADCs, checkpoint inhibitors, radio therapies, and immune agonists, to unlock
greater tumor control. The session will cover how multi-mechanism combinations can overcome tumor heterogeneity, epitope spreading, and immune resistance, ensuring longer-lasting anti-tumor responses.
Discussion Points:
- Exploring the synergy between T cell engagers and standard therapies like checkpoint inhibitors, chemotherapy, and radiotherapy to enhance tumor elimination and epitope spreading
- Identifying next-gen combinations with immune agonists, co-stimulatory molecules, and targeted therapies to increase T cell activity and drive durable anti-tumor responses
- Evaluating novel approaches to combination strategies, balancing efficacy, safety, and immune activation for optimal therapeutic outcomes